Talking Precision Medicine

Rafael Rosengarten talks with NVIDIA’s Stacie Calad-Thomson about connecting AI-driven drug discovery to physical laboratory work. They examine why consistent experimental data is essential, how agents and robotics could coordinate experiments, and how scientists’ responsibilities may change as laboratories automate. The discussion distinguishes proposing molecules or experiments from executing them, validating results and deciding the next research step.

Hosted by Rafael Rosengarten

Rafael Rosengarten and BioPharmaTrend co-founder Andrii Buvailo discuss how to assess progress in AI-assisted drug discovery. They trace the move from individual computational tasks to connected research workflows and question whether counting AI-associated drug candidates captures the technology’s value. Topics include research productivity, trial design, biomarkers, human expertise and the use of patient-derived data, organoids and other representative biological systems to improve translation. The conversation also considers why AI has become polarising and how specialised models may fit into pharmaceutical research.

Tim Wahlberg of CAS speaks with Rafael Rosengarten about the role of curated chemical knowledge in AI-assisted drug discovery. They examine scientific data quality, harmonisation and expert curation, and consider how reliable information can help researchers formulate questions and evaluate answers from large language models.

Hosted by Rafael Rosengarten

Jacob Hooker of Sensorium Therapeutics speaks with Rafael Rosengarten about investigating plant-derived compounds for psychiatric and neurological drug development. They discuss ethnobotanical records, knowledge graphs and AI as tools for generating hypotheses, alongside the medicinal chemistry and clinical testing needed to turn potential leads into medicines.

Hosted by Rafael Rosengarten